<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509078</url>
  </required_header>
  <id_info>
    <org_study_id>PETAL01ROSE</org_study_id>
    <secondary_id>1U01HL123009-01</secondary_id>
    <nct_id>NCT02509078</nct_id>
  </id_info>
  <brief_title>Reevaluation Of Systemic Early Neuromuscular Blockade</brief_title>
  <acronym>ROSE</acronym>
  <official_title>Reevaluation Of Systemic Early Neuromuscular Blockade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a
      patient with acute respiratory distress syndrome will improve survival. Half of the patients
      will receive a neuromuscular blocker for two days and in the other half the use of
      neuromuscular blockers will be discouraged.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      To assess the efficacy and safety of early neuromuscular blockade in reducing mortality and
      morbidity in patients with moderate-severe ARDS, in comparison to a control group with no
      routine early neuromuscular blockade (NMB).

      PRIMARY HYPOTHESIS:

      Early neuromuscular blockade will improve mortality prior to discharge home before day 90, in
      patients with moderate-severe ARDS.

      The trial will accrue a maximum of 1408 patients. Patients will be recruited from the
      emergency departments, intensive care units and other acute care areas of the PETAL Network
      Clinical Centers and randomized to the active (NMB) or control. The overall strategy is to
      screen, consent, and enroll early, every newly intubated, acutely ill or post-operative,
      eligible patient at each site, using clinically obtained pulse oximetry and blood gases.

      By preventing active expiration, and/or patient ventilator dyssynchrony, neuromuscular
      blockade may create a more homogenous distribution of airway pressures and tidal volumes,
      preventing barotrauma/volutrauma and &quot;atelectrauma&quot; resulting in less ventilator-induced lung
      injury.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2016</start_date>
  <completion_date type="Actual">April 4, 2019</completion_date>
  <primary_completion_date type="Actual">July 3, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital Mortality to Day 90</measure>
    <time_frame>90 days after randomization</time_frame>
    <description>The percentage of subjects alive at study day 90. Those subjects discharged home prior to day 90 were counted as alive at day 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Ventilator Free Days to Day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Organ Failure Free Days to Day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>SOFA (Sepsis-related Organ Failure Assessment) was used to determine criteria for an organ failure free day. Scores were based on four of the six SOFA organ categories: Coagulation, Liver, Cardiovascular, and Renal. Each category was scored 0-4; 0 being normal functioning and 4 being the most abnormal. A patient was considered failure free on each day alive with SOFA scores below 2 for all four organ systems.
Ref: Vincent, J.L., et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med, 1996. 22(7): p. 707-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days to Day 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>ICU free days is defined as the number of days between randomization and day 28 in which the patient is in the ICU (for any part of a day).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Hospital Free Days to Days 28</measure>
    <time_frame>28 days after randomization</time_frame>
    <description>Hospital free days are days alive post hospital discharge through day 28. Patients who die on or prior to day 28 are assigned zero hospital free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ-5D-5L): Health Related Quality of Life</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA-Blind: Montreal Cognitive Assessment</measure>
    <time_frame>3 months after randomization</time_frame>
    <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range: 26 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ-5D-5L): Health Related Quality of Life</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol (EQ-5D-5L): Health Related Quality of Life</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA-Blind: Montreal Cognitive Assessment</measure>
    <time_frame>6 months after randomization</time_frame>
    <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA-Blind: Montreal Cognitive Assessment</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1008</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Early Neuromuscular Blockade (NMB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: No Routine Early NMB</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Use of non-study NMB will be discouraged.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisatracurium Besylate</intervention_name>
    <description>Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
    <arm_group_label>Early Neuromuscular Blockade (NMB)</arm_group_label>
    <other_name>Nimbex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Age &gt; 18 years

          2. Presence of all of the following conditions for &lt; 48 hours:

             i. PaO2/FiO2 &lt; 150 with PEEP &gt;/= 8 cm H2O OR, if ABG not available, SaO2/FiO2 ratio
             that is equivalent to a PaO2/FiO2 &lt; 150 with PEEP &gt;/= 8 cm H2O , and a confirmatory
             SaO2/FiO2 ratio that is again equivalent 1-6 hours later

        ii. Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules.

        iii. Respiratory failure not fully explained by cardiac failure or fluid overload; need
        objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk
        factor present.

        Patients must be enrolled within 48 hours of meeting inclusion criteria.

        Exclusion Criteria:

          1. Lack of informed consent

          2. Continuous neuromuscular blockade at enrollment

          3. Known pregnancy

          4. Currently receiving ECMO therapy

          5. Chronic respiratory failure defined as PaCO2 &gt; 60 mm Hg in the outpatient setting

          6. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for
             CPAP/BIPAP used solely for sleep-disordered breathing

          7. Actual body weight exceeding 1 kg per centimeter of height

          8. Severe chronic liver disease defined as a Child-Pugh score of 12-15 (Appendix A2)

          9. Bone marrow transplantation within the last 1 year

         10. Expected duration of mechanical ventilation of &lt; 48 hours

         11. Decision to withhold life-sustaining treatment; except in those patients committed to
             full support except cardiopulmonary resuscitation if an actual cardiac arrest occurs

         12. Moribund patient not expected to survive 24 hours; if CPR provided, assess for
             moribund status greater than 6 from CPR conclusion

         13. Diffuse alveolar hemorrhage from vasculitis

         14. Burns &gt; 70% total body surface

         15. Unwillingness to utilize the ARDS Network 6 ml/kg IBW ventilation protocol

         16. Previous hypersensitivity or anaphylactic reaction to cisatracurium

         17. Neuromuscular conditions that may potentiate neuromuscular blockade and/or impair
             spontaneous ventilation (Appendix A2)

         18. Neurologic conditions undergoing treatment for intracranial hypertension

         19. Enrollment in an interventional ARDS trial with direct impact on neuromuscular
             blockade and PEEP

         20. &gt;120 hours of mechanical ventilation

         21. P/F &lt; 200 mmHg at the time of randomization (if available)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A. Schoenfeld, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Long Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian/Mercy/Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKay-Dee Hospital</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University or Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VCU Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital Cherry Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital First Hill</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://petalnet.org</url>
    <description>Website for the PETAL Network</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <results_first_submitted>June 20, 2019</results_first_submitted>
  <results_first_submitted_qc>July 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2019</results_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Boyd Taylor Thompson</investigator_full_name>
    <investigator_title>Prinicipal Investigator PETAL CCC</investigator_title>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>neuromuscular blocker</keyword>
  <keyword>cisatracurium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisatracurium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be collected electronically and stored at the Clinical Coordinating Center at MGH. A de-identified database of all data will be available for use 3 years after the primary publication. Data can be accessed at that point via the NHLBI BioLINCC data repository.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02509078/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02509078/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Early Neuromuscular Blockade (NMB)</title>
          <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
        </group>
        <group group_id="P2">
          <title>Control: No Routine Early NMB</title>
          <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="506"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="501"/>
                <participants group_id="P2" count="505"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Neuromuscular Blockade (NMB)</title>
          <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
        </group>
        <group group_id="B2">
          <title>Control: No Routine Early NMB</title>
          <description>Use of non-study NMB will be discouraged.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="501"/>
            <count group_id="B2" value="505"/>
            <count group_id="B3" value="1006"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="358"/>
                    <measurement group_id="B3" value="706"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="14.7"/>
                    <measurement group_id="B2" value="55.1" spread="15.9"/>
                    <measurement group_id="B3" value="55.8" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="410"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="831"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="360"/>
                    <measurement group_id="B2" value="343"/>
                    <measurement group_id="B3" value="703"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="501"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="1006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hospital Mortality to Day 90</title>
        <description>The percentage of subjects alive at study day 90. Those subjects discharged home prior to day 90 were counted as alive at day 90.</description>
        <time_frame>90 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Mortality to Day 90</title>
          <description>The percentage of subjects alive at study day 90. Those subjects discharged home prior to day 90 were counted as alive at day 90.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Alive at Day 90</title>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="289"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dead Prior to Day 90</title>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Wald test for the difference of two prop</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>5.9</ci_upper_limit>
            <estimate_desc>Estimated value is a percentage</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Ventilator Free Days to Day 28</title>
        <description>Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.</description>
        <time_frame>28 days after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Ventilator Free Days to Day 28</title>
          <description>Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.</description>
          <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="10.4"/>
                    <measurement group_id="O2" value="9.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Organ Failure Free Days to Day 28</title>
        <description>SOFA (Sepsis-related Organ Failure Assessment) was used to determine criteria for an organ failure free day. Scores were based on four of the six SOFA organ categories: Coagulation, Liver, Cardiovascular, and Renal. Each category was scored 0-4; 0 being normal functioning and 4 being the most abnormal. A patient was considered failure free on each day alive with SOFA scores below 2 for all four organ systems.
Ref: Vincent, J.L., et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med, 1996. 22(7): p. 707-10.</description>
        <time_frame>28 days after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Organ Failure Free Days to Day 28</title>
          <description>SOFA (Sepsis-related Organ Failure Assessment) was used to determine criteria for an organ failure free day. Scores were based on four of the six SOFA organ categories: Coagulation, Liver, Cardiovascular, and Renal. Each category was scored 0-4; 0 being normal functioning and 4 being the most abnormal. A patient was considered failure free on each day alive with SOFA scores below 2 for all four organ systems.
Ref: Vincent, J.L., et al., The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med, 1996. 22(7): p. 707-10.</description>
          <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="480"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="11.3"/>
                    <measurement group_id="O2" value="12.5" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ICU Free Days to Day 28</title>
        <description>ICU free days is defined as the number of days between randomization and day 28 in which the patient is in the ICU (for any part of a day).</description>
        <time_frame>28 days after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
        </group_list>
        <measure>
          <title>ICU Free Days to Day 28</title>
          <description>ICU free days is defined as the number of days between randomization and day 28 in which the patient is in the ICU (for any part of a day).</description>
          <population>The overall number of participants analyzed reflects the number of patients that had sufficient data to allow for calculation of the outcome measure.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="500"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="9.4"/>
                    <measurement group_id="O2" value="9.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Hospital Free Days to Days 28</title>
        <description>Hospital free days are days alive post hospital discharge through day 28. Patients who die on or prior to day 28 are assigned zero hospital free days.</description>
        <time_frame>28 days after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Hospital Free Days to Days 28</title>
          <description>Hospital free days are days alive post hospital discharge through day 28. Patients who die on or prior to day 28 are assigned zero hospital free days.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="501"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="7.8"/>
                    <measurement group_id="O2" value="5.9" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
        <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
        <time_frame>3 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
          <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.7"/>
                    <measurement group_id="O2" value="3.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
        <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
        <time_frame>3 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
          <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="0.41" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.44" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</title>
        <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</title>
          <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MoCA-Blind: Montreal Cognitive Assessment</title>
        <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range: 26 or greater.</description>
        <time_frame>3 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>MoCA-Blind: Montreal Cognitive Assessment</title>
          <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range: 26 or greater.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="5.2"/>
                    <measurement group_id="O2" value="22.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
        <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
          <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="2.4"/>
                    <measurement group_id="O2" value="2.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
        <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
        <time_frame>12 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisastracurium besylate for the first 48 hours of the trial.
cisastracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisastracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>Katz Activities of Daily Living (ADL)/Lawton Instrumental Activities Of Daily Living Scale (IADL)</title>
          <description>Assesses whether individual can living independently and assess a range of common functional activities, from walking and toileting to managing money and cooking meals. Data is a pooled estimates from patient survey and proxy survey. The total score is rated from 0 to 10 (MCID=1; 1 point=1 ADL); a higher score indicates having more difficulties in daily activities.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="2.6"/>
                    <measurement group_id="O2" value="2.4" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
        <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
          <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.57" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.55" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
        <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
        <time_frame>12 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol (EQ-5D-5L): Health Related Quality of Life</title>
          <description>Using a standardized scale, do health reasons limit the person's ability to enjoy their life? Pooled estimates from patient survey and proxy survey were used. Utility index was computed from a lookup table according to EQ-5D-5L response profiles; utility index ranges from -0.11 to 1.00 (higher scores are better; 1.00 is perfect health), minimal clinically important difference (MCID) is 0.07</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0.57" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.77" lower_limit="0.57" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MoCA-Blind: Montreal Cognitive Assessment</title>
        <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
        <time_frame>6 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>MoCA-Blind: Montreal Cognitive Assessment</title>
          <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="4.8"/>
                    <measurement group_id="O2" value="23.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MoCA-Blind: Montreal Cognitive Assessment</title>
        <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
        <time_frame>12 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>MoCA-Blind: Montreal Cognitive Assessment</title>
          <description>How clearly can patient think and recall things? MoCA-Blind is only asked in patient survey; total score is rated from 0 to 30 and a higher score indicates better cognitive performance. Normal range:
26 or greater.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" spread="4.9"/>
                    <measurement group_id="O2" value="24.0" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</title>
        <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
        <time_frame>12 months after randomization</time_frame>
        <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Early Neuromuscular Blockade (NMB)</title>
            <description>Patients will receive cisatracurium besylate for the first 48 hours of the trial.
cisatracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
          </group>
          <group group_id="O2">
            <title>Control: No Routine Early NMB</title>
            <description>Use of non-study NMB will be discouraged.</description>
          </group>
        </group_list>
        <measure>
          <title>PTSS-14: Post-traumatic Stress-like Symptoms Scores &gt;/= 45</title>
          <description>Does the patient have symptoms of anxiety and stress from their ICU stay? PTSS-14 is only asked at month 6 and month 12 in patient survey; total score is rated from 14 to 98 and a higher score indicates having more post-traumatic stress syndrome related symptoms. Participants with scores greater than or equal to 45 were reported.</description>
          <population>The overall number of participants analyzed reflects the number of patients that were alive, able to be contacted, and had sufficient data to allow for calculation of the outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects were assessed for occurrence of adverse events from time of randomization through study day 7 (five days after infusion of study drug) or ICU discharge, whichever occurred first.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Early Neuromuscular Blockade (NMB)</title>
          <description>Patients will receive cisastracurium besylate for the first 48 hours of the trial.
cisastracurium besylate: Patients randomized to the early neuromuscular blockade arm will receive a cisastracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
        </group>
        <group group_id="E2">
          <title>Control: No Routine Early NMB</title>
          <description>Use of non-study NMB will be discouraged. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="216" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Methemoglobinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AV Block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation with RVR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Tachycardia Supraventricular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Torsades De Pointe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Heart Block Av 3rd Degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Necrosis of left foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Reaction Febrile</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infartion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>CVA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hemmorage Brain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Subdural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Bleeding Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hemorrhage Brain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Subarachnoid Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Airway Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Embolus Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Laceration Diaphragm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation Paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac Arrhythmia (Nos)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Severe Prolonged Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Vasovagal Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Paralysis Awareness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Subcutaneous Emphysema And Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Stoma Leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Superficial Venous Thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hemorrhage Retroperitoneal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="505"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="501"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="505"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In addition to the restriction on the PI for sponsor to review results prior to public release within 60 days, there is a network provision: The Publications Committee of the PETAL Network must review and approve all pre-submission PETAL Network studies before publication or presentation. Manuscripts comparing outcomes of PETAL study endpoints from one center to the reminder of the group are not permitted.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katie Oldmixon</name_or_title>
      <organization>Mass General Hospital (PETAL Clinical Coordinating Center)</organization>
      <phone>617-726-4777</phone>
      <email>coldmixon@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

